Maverick takeout adds T cell-engagers to Takeda’s solid tumor toolkit

The acquisition fits squarely in Takeda’s transformation from a small molecule company to one built on multiple modalities. 

March 10, 2021 1:56 AM UTC

The addition of Maverick’s T cell-engaging bispecifics technology to Takeda’s solid tumor toolkit is the latest move by the Japanese pharma to transform its ...

Access this Article